Table 1.
Patient and Disease Characteristics
| Characteristic | Total (N = 27) | |
|---|---|---|
| N | % or Median (q1-q3) | |
| Age at diagnosis, y | 26 | 63 (59-75) |
| Gleason score | ||
| ≤6 | 2 | 7 |
| 7 | 10 | 37 |
| ≥8 | 14 | 51 |
| Unknown | 1 | 4 |
| Prior radical prostatectomy | 7 | 26 |
| Prior radiation therapy | 16 | 59 |
| Prior chemotherapy | 1 | 4 |
| Baseline ARMOR2 | ||
| Age, y | 27 | 70 (65-78) |
| Presence of metastases | ||
| No | 5 | 19 |
| Yes | 22 | 81 |
| Sites of metastasis | ||
| Bone | 15 | 56 |
| Bone only | 9 | 33 |
| Lymph node | 12 | 44 |
| Other | 2 | 7 |
| Laboratory data | ||
| PSA, ng/mL | 27 | 18.7 (9.1-45.7) |
| Alkaline phosphatase, U/L | 25 | 84 (69-100) |
| Calcium, mg/dL | 25 | 9.4 (9.2-9.6) |
| Hemoglobin, g/dL | 24 | 12.7 (12.0-13.6) |
| Platelet count, k/uL | 27 | 224 (188-265) |
| On ARMOR2 | ||
| Nadir PSA, ng/mL | 27 | 9.6 (3.0-40.7) |
| Time to nadir PSA from baseline, d | 27 | 28 (14-42) |
| Percent PSA drop | 27 | −49% (−74% to −3%) |
| End of ARMOR2 | ||
| End of treatment PSA, ng/mL | 27 | 24.8 (6.4-86.9) |
| Reason for treatment discontinuation | ||
| Progression | 18 | 67 |
| Toxicity | 6 | 22 |
| Other/unknown | 3 | 11 |
| Progression type | ||
| Clinical progression only | 1 | 4 |
| PSA progression only | 10 | 37 |
| Radiographic progression only | 3 | 11 |
| Clinical and PSA progression | 1 | 4 |
| PSA and radiographic progression | 3 | 11 |
Abbreviations: ARMOR = Androgen Receptor Modulation Optimized for Response; PSA = prostate-specific antigen.